Twenty-five (24.8%) indeterminate nodules presented mutations in cytology samples, with one RAS mutation in a benign lesion and twenty-four in malignant tumors, being thirteen (17.3%) for RAS mutation, seven (9.3%) for BRAF, and four (5.6%) for TERTp mutation. Here, BRAF is linked to cancer.